Press release
Mantle Cell Lymphoma Pipeline Drug Analysis 2025: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight
Mantle Cell Lymphoma Pipeline
(Albany, USA) DelveInsight's, "Mantle Cell Lymphoma Pipeline Insight, 2025," report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Mantle Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report provides a detailed description of the Mantle Cell Lymphoma drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The Mantle Cell Lymphoma pipeline report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Discover the latest drugs and treatment options in the Mantle Cell Lymphoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Mantle Cell Lymphoma Pipeline Outlook [https://www.delveinsight.com/report-store/mantle-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the Mantle Cell Lymphoma Pipeline Report
* DelveInsight's Mantle Cell Lymphoma pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Mantle Cell Lymphoma treatment.
* In April 2025, BeiGene announced results of a Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma
* In April 2025, Loxo Oncology announced results of a Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naive Mantle Cell Lymphoma (BRUIN MCL-321)
* In January 2025, AstraZeneca's CALQUENCE Registered (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.
* In October 2024:- Hoffmann-La Roche- The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
* In October 2024:- Loxo Oncology, Inc announced a Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL). This study includes 3 parts: Phase 1 (pirtobrutinib monotherapy dose escalation and dose expansion), Phase 1b (pirtobrutinib combination therapy dose expansion), and Phase 2 (pirtobrutinib monotherapy dose expansion).
* Key mantle cell lymphoma companies such as AbbVie, Adicet Bio, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Nurix, LegoChem Biosciences, Xynomic Pharmaceuticals, Merck & Co, Incyte Corporation, TG Therapeutics, Janssen/Pharmacyclics, Eternity Bioscience, Traws Pharm, Advenchen Laboratories, and others are evaluating new mantle cell lymphoma drugs to improve the treatment landscape.
* Promising mantle cell lymphoma pipeline therapies such as Venetoclax, ADI-001, Orelabrutinib, LP-168, BGB-11417, NX 2127, LCB 71, NX 5948, Abexinostat, Pembrolizumab, Parsaclisib, Umbralisib, Ibrutinib, Edralbrutinib, Narazaciclib, Lucitanib, and others are under different phases of mantle cell lymphoma clinical trials.
Stay ahead with the most recent pipeline outlook for Mantle Cell Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Mantle Cell Lymphoma Treatment Drugs [https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Mantle Cell Lymphoma Emerging Drugs Profile
* Venetoclax: AbbVie
Venetoclax is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis.
* Ixazomib: Takeda
Ixazomib belongs to a class of drugs called proteasome inhibitors, which work by blocking the action of proteasomes, cellular structures responsible for breaking down proteins. By inhibiting proteasomes, ixazomib helps to disrupt the growth and survival of cancer cells. Currently, the product is in the Phase II stage of its development for the treatment of mantle cell lymphoma.
* ADI-001: Adicet Bio
ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent antitumor activity in preclinical models, leading to long-term control of tumor growth. ADI-001 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in the Phase I stage of its development for the treatment of mantle cell lymphoma.
Explore groundbreaking therapies and clinical trials in the Mantle Cell Lymphoma Pipeline. Access DelveInsight's detailed report now! @ New Mantle Cell Lymphoma Drugs [https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Mantle Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Mantle Cell Lymphoma Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Mantle Cell Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Mantle Cell Lymphoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of the Mantle Cell Lymphoma Pipeline Report
* Coverage- Global
* Key Mantle cell lymphoma companies: AbbVie Inc. (NYSE: ABBV), Adicet Bio, Inc. (NASDAQ: ACET), InnoCare Pharma Ltd. (HKEX: 9969), BeiGene, Ltd. (NASDAQ: BGNE), Nurix Therapeutics, Inc. (NASDAQ: NRIX), LegoChem Biosciences, Inc. (KOSDAQ: 141080), Xynomic Pharmaceuticals Holdings, Inc. (NASDAQ: XYN), Merck & Co., Inc. (NYSE: MRK), Incyte Corporation (NASDAQ: INCY), TG Therapeutics, Inc. (NASDAQ: TGTX), Janssen/Pharmacyclics (acquired by Johnson & Johnson and AbbVie respectively, not independently listed), Advenchen Laboratories, Eternity Bioscience, Traws Pharm, Guangzhou Lupeng Pharmaceutical Company LTD, and others.
* Mantle cell lymphoma therapies: Venetoclax, ADI-001, Orelabrutinib, LP-168, BGB-11417, NX 2127, LCB 71, NX 5948, Abexinostat, Pembrolizumab, Parsaclisib, Umbralisib, Ibrutinib, Edralbrutinib, Narazaciclib, Lucitanib, and others.
* Mantle Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Mantle Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Mantle Cell Lymphoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Mantle Cell Lymphoma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Content
* Introduction
* Executive Summary
* Mantle Cell Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Mantle Cell Lymphoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Venetoclax: AbbVie
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Ixazomib: Takeda
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ADI-001: Adicet Bio
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Mantle Cell Lymphoma Key Companies
* Mantle Cell Lymphoma Key Products
* Mantle Cell Lymphoma- Unmet Needs
* Mantle Cell Lymphoma- Market Drivers and Barriers
* Mantle Cell Lymphoma- Future Perspectives and Conclusion
* Mantle Cell Lymphoma Analyst Views
* Mantle Cell Lymphoma Key Companies
* Appendix
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=mantle-cell-lymphoma-pipeline-drug-analysis-2025-clinical-trials-ema-pdma-fda-approvals-medication-therapies-mechanism-of-action-roa-ind-nda-approval-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mantle Cell Lymphoma Pipeline Drug Analysis 2025: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight here
News-ID: 4054339 • Views: …
More Releases from ABNewswire
Tiki Hut Highlights Bike & Beach Chair Rentals for Hilton Head Island Visitors i …
Tiki Hut, a Hilton Head Island tradition for more than 40 years, is making it easier than ever for locals and vacationers to enjoy the island's natural beauty with its bike and beach chair rental services.
Hilton Head Island, SC - August 28, 2025 - Tiki Hut, a Hilton Head Island tradition for more than 40 years, is making it easier than ever for locals and vacationers to enjoy the island's…
Dr. Anil Shah Enhances Patient Recovery with Wellness-Focused Surgical and Recov …
New York, NY & Chicago, IL - Dr. Anil Shah, a nationally recognized facial plastic surgeon, is elevating the patient experience by introducing wellness-focused surgical practices that enhance healing and recovery. At his offices in both New York and Chicago, Dr. Shah offers patients a calming and restorative environment that blends cutting-edge surgical care with supportive therapies designed to help the body recover faster and more comfortably.
Central to this initiative…
VagiThera Bringing Premium At-Home Ultrasound Skincare to Life
Image: https://www.abnewswire.com/upload/2025/08/67bb95286bac3d1e681743233661f729.jpg
Attibe Beauty is proud to announce the Indiegogo launch of VagiThera [https://www.vagithera.com/], a premium at-home wellness device designed to empower women with precise, safe, and convenient skincare for delicate areas. Combining 360 degrees rotating micro-focused ultrasound (MFU) technology with ergonomic, wireless design, VagiThera brings professional-grade care into the comfort of home.
Developed over 8 years in collaboration with certified Korean wellness technology experts, VagiThera targets sensitive zones often left untouched…
New Book by Dr. Pietro Emanuele Garbelli Charts a Bold Path for Physicians in th …
As artificial intelligence, robotics, and automation revolutionize modern healthcare, the question looms: What will be the role of the doctor in this new era?
In his groundbreaking new book, The Doctor's Future (Balboa Press, ISBN: 9798765257791), Dr. Pietro Emanuele Garbelli answers with a clear, actionable roadmap for physicians and healthcare leaders to not only adapt but lead.
Drawing on over two decades of frontline medical experience and high-level consulting, Dr. Garbelli introduces…
More Releases for Mantle
Key Factor Supporting Mantle Cell Lymphoma Therapeutics Market Development in 20 …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Mantle Cell Lymphoma Therapeutics Market Size By 2025?
The market size of therapeutics for mantle cell lymphoma has seen a steady uptick in the past few years. It is anticipated to enhance from $2.42 billion in 2024 to $2.62 billion in 2025, with a compound…
Emerging Trends Influencing The Growth Of The Mantle Cell Lymphoma Therapeutics …
The Mantle Cell Lymphoma Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Mantle Cell Lymphoma Therapeutics Market Size Expected to Be by 2034?
The Mantle Cell Lymphoma Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering…
Mantle Cell Lymphoma Therapeutics Market Size, Share, Growth, Trends, Analysis a …
The global mantle cell lymphoma therapeutics market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). Mantle cell lymphoma is a rare form of B-cell non-Hodgkin lymphoma. It is a form of blood cancer that impacts white blood cells known as lymphocytes. The pivotal factors that are driving the market growth include an increase in the population base suffering from mantle cell lymphoma coupled with the…
Mantle Cell lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unm …
DelveInsight's, "Mantle Cell Lymphoma Pipeline Insight, 2024," report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Mantle Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the…
The Effects Of Material To Mantle And Concave On The Service Life
The Role of Concave and Mantles in Cone Crushers [https://gubtcasting.com/]
Concave and mantles are two of the most critical components of a cone crusher. They are responsible for crushing stones and rocks, and ensuring the production of high-quality aggregates. Concaves are fixed parts that line the top of the crusher frame, while mantles are movable parts that cover the cone. Together, they form the crushing chamber and provide a surface for…
Mantle Cell Lymphoma Therapeutics Market Report 2024: Strategies And Recent Deve …
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2465
The Business Research Company offers in-depth market insights through Mantle Cell Lymphoma Therapeutics Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The mantle cell lymphoma therapeutics market size has grown strongly…
